Elsevier

Experimental Neurology

Volume 155, Issue 2, February 1999, Pages 268-273
Experimental Neurology

Regular Article
Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter

https://doi.org/10.1006/exnr.1998.6995Get rights and content

Abstract

MPTP has been shown to induce parkinsonism both in human and in nonhuman primates. The precise mechanism of dopaminergic cell death induced following MPTP treatment is still subject to intense debate. MPP+, which is the oxidation product of MPTP, is actively transported into presynaptic dopaminergic nerve terminals through the plasma membrane dopamine transporter (DAT). In this study, we used mice lacking the DAT by homologous recombination and demonstrated that the MPTP-induced dopaminergic cell loss is dependent on the presence of the DAT. For this we have used tyrosine hydroxylase immunoreactivity (TH-IR) labeling of dopamine cells of the substantia nigra compacta in wild-type, heterozygote, and homozygote mice that were given either saline or MPTP treatments (two ip injections of 30 mg/kg, 10 h apart). Our results show a significant loss of TH-IR in wild type (34.4%), less loss in heterozygotes (22.5%), and no loss in homozygote animals. Thus dopamine cell loss is related to levels of the DAT. These results shed light on the degenerative process of dopamine neurons and suggest that individual differences in developing Parkinson's disease in human may be related to differences of uptake through the DAT of a yet unidentified neurotoxin.

References (39)

  • V. Jackson-Lewis et al.

    Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

    Neurodegeneration

    (1995)
  • Z.L. Rossetti et al.

    MPTP and free radicals in vitro

    Biochem. Pharmacol.

    (1988)
  • W. Schultz et al.

    Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism

    Neurosci. Lett.

    (1985)
  • S. Shimada et al.

    Dopamine transporter mRNA: Dense expression in ventral midbrain neurons

    Mol. Brain Res.

    (1992)
  • P.K. Sonsalla et al.

    The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice

    Eur. J. Pharmacol.

    (1986)
  • M.J. Bannon et al.

    Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age

    Proc. Natl. Acad. Sci. USA

    (1992)
  • A. Benazzouz et al.

    MPTP-induced hemiparkinsonism in monkeys: Behavioral, mechanographic, electromyographic and immunohistochemical studies

    Exp. Brain Res.

    (1992)
  • E. Bezard et al.

    Kinetics of nigral degeneration in a chronic model of MPTP-treated mice

    Neurosci. Lett.

    (1997)
  • K.J. Buck et al.

    Chimeric dopamine–norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium

    Proc. Natl. Acad. Sci. USA

    (1994)
  • Cited by (185)

    • Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models

      2019, Journal of Biological Chemistry
      Citation Excerpt :

      Although in agreement with studies from other groups (29–33), the microsomal CYP2D6 supported by cytochrome P450 reductase (CYPOR) catalyzed the demethylation of MPTP to nontoxic metabolites. Our results showing the ability of Mt2D6 to metabolize MPTP to the cationic form MPP+ are a paradigm shift because it is widely believed that monoamine oxidase B, present on the mitochondrial outer membrane of glial cells, carries out oxidation of MPTP, and the metabolites are then transported to dopaminergic neurons through dopamine transporters (28, 34–37). Both monoamine oxidase B and dopamine transporters have been targets of drug development for PD over the past two to three decades.

    • Chemosensory dysfunction in neurodegenerative diseases

      2019, Handbook of Clinical Neurology
    View all citing articles on Scopus

    Abbreviations used: DAT, dopamine transporter; DAT+/+, wild type; DAT+/−, heterozygote; DAT−/−, homozygote; TH-IR, tyrosine hydroxylase immunoreactivity; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP+, 1-methyl-4-phenylpyridinium; PD, Parkinson's disease; SNc, substantia nigra pars compacta.

    1

    To whom correspondence should be addressed. Fax: 33 5 56 98 61 82. E-mail:[email protected].

    View full text